CN1309721C - β－咔啉衍生物及其抗抑郁和抗焦虑的药物应用 - Google Patents

β－咔啉衍生物及其抗抑郁和抗焦虑的药物应用 Download PDF

Info

Publication number
CN1309721C
CN1309721C CNB028077814A CN02807781A CN1309721C CN 1309721 C CN1309721 C CN 1309721C CN B028077814 A CNB028077814 A CN B028077814A CN 02807781 A CN02807781 A CN 02807781A CN 1309721 C CN1309721 C CN 1309721C
Authority
CN
China
Prior art keywords
compound
formula
alkyl
anxiety
free alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028077814A
Other languages
English (en)
Chinese (zh)
Other versions
CN1500090A (zh
Inventor
T·J·特罗克斯勒
K·胡尔特
D·霍耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1500090A publication Critical patent/CN1500090A/zh
Application granted granted Critical
Publication of CN1309721C publication Critical patent/CN1309721C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB028077814A 2001-04-03 2002-04-02 β－咔啉衍生物及其抗抑郁和抗焦虑的药物应用 Expired - Fee Related CN1309721C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0108337.7 2001-04-03
GBGB0108337.7A GB0108337D0 (en) 2001-04-03 2001-04-03 Organic compounds

Publications (2)

Publication Number Publication Date
CN1500090A CN1500090A (zh) 2004-05-26
CN1309721C true CN1309721C (zh) 2007-04-11

Family

ID=9912165

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028077814A Expired - Fee Related CN1309721C (zh) 2001-04-03 2002-04-02 β－咔啉衍生物及其抗抑郁和抗焦虑的药物应用

Country Status (27)

Country Link
US (1) US6861430B2 (https=)
EP (1) EP1377578B1 (https=)
JP (1) JP4405732B2 (https=)
KR (1) KR100564840B1 (https=)
CN (1) CN1309721C (https=)
AR (1) AR035451A1 (https=)
AT (1) ATE517104T1 (https=)
AU (1) AU2002316828B2 (https=)
BR (1) BR0208566B1 (https=)
CA (1) CA2440014C (https=)
CZ (1) CZ295992B6 (https=)
EC (1) ECSP034754A (https=)
ES (1) ES2368389T3 (https=)
GB (1) GB0108337D0 (https=)
HU (1) HUP0400317A3 (https=)
IL (1) IL157545A0 (https=)
MX (1) MXPA03009057A (https=)
MY (1) MY134026A (https=)
NO (1) NO20034413L (https=)
NZ (1) NZ528370A (https=)
PE (1) PE20021018A1 (https=)
PL (1) PL210861B1 (https=)
PT (1) PT1377578E (https=)
RU (1) RU2003130644A (https=)
SK (1) SK12222003A3 (https=)
WO (1) WO2002081471A1 (https=)
ZA (1) ZA200306108B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
ES2427166T3 (es) * 2003-06-23 2013-10-29 Ono Pharmaceutical Co., Ltd. Compuesto heterocíclico tricíclico novedoso
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
WO2006068164A1 (ja) * 2004-12-22 2006-06-29 Ono Pharmaceutical Co., Ltd. 三環式化合物およびその用途
US7879859B2 (en) 2005-11-21 2011-02-01 Merck Sharp & Dohme Corp. Diagnosis and treatment of type 2 diabetes and other disorders
WO2007062175A2 (en) * 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
EP2178537A4 (en) * 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
WO2009016329A1 (en) * 2007-07-31 2009-02-05 Cambridge Enterprise Limited Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions
US8338604B2 (en) 2008-06-20 2012-12-25 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
CN102695414A (zh) 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
CN111349096B (zh) * 2020-04-14 2021-03-09 石河子大学 一种吲哚类化合物及其制备方法、应用
KR102467844B1 (ko) 2021-04-21 2022-11-16 삼성전자주식회사 솔리드 스테이트 드라이브 장치 및 이를 포함하는 데이터 저장 장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348958A (en) * 1991-06-05 1994-09-20 Schering Aktiengesellschaft Hetaryloxy-β-carbolines, and use as pharmaceutical agents for treating epilepsy and anxiety
WO1999064420A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S β-CARBOLINE COMPOUNDS
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348958A (en) * 1991-06-05 1994-09-20 Schering Aktiengesellschaft Hetaryloxy-β-carbolines, and use as pharmaceutical agents for treating epilepsy and anxiety
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
WO1999064420A1 (en) * 1998-06-12 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S β-CARBOLINE COMPOUNDS

Also Published As

Publication number Publication date
IL157545A0 (en) 2004-03-28
PE20021018A1 (es) 2003-01-13
KR20040008150A (ko) 2004-01-28
HUP0400317A2 (hu) 2004-09-28
US20040132735A1 (en) 2004-07-08
CZ20032655A3 (cs) 2003-12-17
CA2440014C (en) 2010-11-23
NO20034413D0 (no) 2003-10-02
CN1500090A (zh) 2004-05-26
AU2002316828B2 (en) 2006-05-11
BR0208566A (pt) 2004-03-30
JP2004525178A (ja) 2004-08-19
SK12222003A3 (sk) 2004-06-08
HUP0400317A3 (en) 2007-10-29
PL210861B1 (pl) 2012-03-30
KR100564840B1 (ko) 2006-03-28
JP4405732B2 (ja) 2010-01-27
ECSP034754A (es) 2003-10-28
EP1377578A1 (en) 2004-01-07
ATE517104T1 (de) 2011-08-15
NZ528370A (en) 2005-10-28
ES2368389T3 (es) 2011-11-16
US6861430B2 (en) 2005-03-01
BR0208566B1 (pt) 2013-12-24
NO20034413L (no) 2003-10-02
RU2003130644A (ru) 2005-04-10
CZ295992B6 (cs) 2005-12-14
WO2002081471A1 (en) 2002-10-17
ZA200306108B (en) 2004-07-05
GB0108337D0 (en) 2001-05-23
PT1377578E (pt) 2011-09-23
EP1377578B1 (en) 2011-07-20
PL362571A1 (en) 2004-11-02
CA2440014A1 (en) 2002-10-17
MXPA03009057A (es) 2004-02-12
MY134026A (en) 2007-11-30
AR035451A1 (es) 2004-05-26

Similar Documents

Publication Publication Date Title
CN1309721C (zh) β－咔啉衍生物及其抗抑郁和抗焦虑的药物应用
JP4347125B2 (ja) 四環式誘導体の中間体
JP4012246B2 (ja) 化学物質
JP5580731B2 (ja) 置換された２，３，４，５−テトラヒドロ−１ｈ−ピリド［４，３−ｂ］インドール、その製造のための方法及び使用
US7388019B2 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2010510211A (ja) 免疫抑制用７−置換プリン誘導体
CN1193964A (zh) 苯并[g]喹啉衍生物
CN102482287B (zh) 作为C-Met酪氨酸激酶调节剂的3-杂芳基甲基-咪唑并[1,2-B]哒嗪-6-基衍生物
AU2002316828A1 (en) Beta-carboline derivatives and its pharmaceutical use against depression and anxiety
CN1097459C (zh) 用作磷酸二酯酶iv抑制剂的二氮杂䓬并吲哚
HUP9904623A2 (hu) 1H-Pirido[3,4-b]indol-4-karboxamid-származékok,eljárás előállításukra és alkalmazásuk a gyógyászatban
HUP0003118A2 (hu) 2,7-Szubsztituált oktahidro-1H-pirido-[1,2-a]pirazin-származékok alkalmazása gyógyszerkészítmények előállítására
JP2008519818A (ja) Ｃｎｓ障害の治療のためのアザベンゾオキサゾール
JP5563559B2 (ja) ２−アミノ−３−スルホニル−テトラヒドロピラゾロ［１，５−ａ］ピリド−ピリミジン−セロトニン５−ＨＴ６受容体アンタゴニスト、調製のための方法及びその使用
JP2018150349A (ja) ヘテロアリール化合物及びその使用方法
TWI670271B (zh) [1,2,4]三唑并[4,3-a]吡-6(5h)-酮衍生物
US20060166974A1 (en) Azabenzoxazoles for the treatment of CNS disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070411

Termination date: 20140402